Skip to main content

Your HP Hardware and Firmware Security Bulletin Notification

===========================================



HP Support Alerts

Your source for HP drivers, firmware, patches, security bulletins

and support





Critical Security Bulletins - 03/30/2015

HPSBHF03271 rev.1 - HP PCs and Workstations Running Windows 7 with NVidia Graphics Driver, Elevation of Privileges

http://alerts.hp.com/r?2.1.3KT.2ZR.1DDl4I.LoI6v2..T.iX68.8tFy.bW89MQ%5f%5fCbReFOc0

Content Type: HP Hardware and Firmware

OS: ALL





_____________________________________________________________________



Alerts Priority Definitions



Critical:

Refers to a critical issue you need to be aware of. Often includes an

immediate application that is necessary to protect you from an

unrecoverable failure such as data corruption or loss, hardware

damage or unrecoverable lockup or hang. You could be at risk of a

serious unrecoverable error if action is not taken.



Recommended:

Refers to important product or system information. Suggested

improvements should be applied at your earliest convenience. There is

potential for sub-optimal performance, lock-ups or unwanted

shutdowns. This will protect your system from a serious, but not

unrecoverable failure.



Routine:

Refers to information and applications that can help you manage your

system, such as performance upgrades and best practices. These

enhancements can be added at your discretion to help optimize your

HP product.

_____________________________________________________________________



My info



Edit my profile

http://alerts.hp.com/r?2.1.3KT.2ZR.1DDl4I.LoI6v2..T.bCHs.8tFy.bW89MQ%5f%5fDAROFQN0



My recent alerts

http://alerts.hp.com/r?2.1.3KT.2ZR.1DDl4I.LoI6v2..T.bCHu.8tFy.bW89MQ%5f%5fDAYCFQP0



My products

http://alerts.hp.com/r?2.1.3KT.2ZR.1DDl4I.LoI6v2..T.bCHw.8tFy.bW89MQ%5f%5fDAeWFQR0

_____________________________________________________________________



++ Computers ++

Laptops

http://alerts.hp.com/r?2.1.3KT.2ZR.1DDl4I.LoI6v2..T.bCHy.8tFy.bW89MQ%5f%5fDBFKFQT0



Desktop

http://alerts.hp.com/r?2.1.3KT.2ZR.1DDl4I.LoI6v2..T.bCHy.8tFy.bW89MQ%5f%5fDBFKFQT0



Storage & Servers

http://alerts.hp.com/r?2.1.3KT.2ZR.1DDl4I.LoI6v2..T.bCH%5f.8tFy.bW89MQ%5f%5fCePGFPZ0



Monitors

http://alerts.hp.com/r?2.1.3KT.2ZR.1DDl4I.LoI6v2..T.bCI0.8tFy.bW89MQ%5f%5fCZWcFOL0



++ Printers ++

Printers & All-in-ones

http://alerts.hp.com/r?2.1.3KT.2ZR.1DDl4I.LoI6v2..T.bCI2.8tFy.bW89MQ%5f%5fCZdQFON0



Ink, Toner and Paper

http://alerts.hp.com/r?2.1.3KT.2ZR.1DDl4I.LoI6v2..T.bCI4.8tFy.bW89MQ%5f%5fCaEEFOP0



Scanners & Fax

http://alerts.hp.com/r?2.1.3KT.2ZR.1DDl4I.LoI6v2..T.bCI6.8tFy.bW89MQ%5f%5fCaKYFOR0



++ Support ++

Business Support Center

http://alerts.hp.com/r?2.1.3KT.2ZR.1DDl4I.LoI6v2..T.bCI8.8tFy.bW89MQ%5f%5fCaRMFOT0



HP Software

http://alerts.hp.com/r?2.1.3KT.2ZR.1DDl4I.LoI6v2..T.bCIA.8tFy.bW89MQ%5f%5fCbPGFOc0



Support forums

http://alerts.hp.com/r?2.1.3KT.2ZR.1DDl4I.LoI6v2..T.bCIC.8tFy.bW89MQ%5f%5fCbVaFOe0



Solutions

http://alerts.hp.com/r?2.1.3KT.2ZR.1DDl4I.LoI6v2..T.bCIE.8tFy.bW89MQ%5f%5fCbcOFPA0



Products & Services

http://alerts.hp.com/r?2.1.3KT.2ZR.1DDl4I.LoI6v2..T.bCIG.8tFy.bW89MQ%5f%5fCcDCFPC0



++ Connect with HP ++

Facebook

http://alerts.hp.com/r?2.1.3KT.2ZR.1DDl4I.LoI6v2..T.bCII.8tFy.bW89MQ%5f%5fCcJWFPE0



Twitter

http://alerts.hp.com/r?2.1.3KT.2ZR.1DDl4I.LoI6v2..T.bCIK.8tFy.bW89MQ%5f%5fCcQKFPG0



LinkedIn

http://alerts.hp.com/r?2.1.3KT.2ZR.1DDl4I.LoI6v2..T.bCIM.8tFy.bW89MQ%5f%5fCcWeFPI0

_____________________________________________________________________





====================================================================



HP.com

http://alerts.hp.com/r?2.1.3KT.2ZR.1DDl4I.LoI6v2..T.buT2.8tFy.bW89MQ%5f%5fDAOQFQK0



Privacy

http://alerts.hp.com/r?2.1.3KT.2ZR.1DDl4I.LoI6v2..T.buT4.8tFy.bW89MQ%5f%5fDAVEFQM0



Unsubscribe

http://alerts.hp.com/r?2.1.3KT.2ZR.1DDl4I.LoI6v2..T.buT6.8tFy.bW89MQ%5f%5fDAbYFQO0



Update Profile

http://alerts.hp.com/r?2.1.3KT.2ZR.1DDl4I.LoI6v2..T.buT8.8tFy.bW89MQ%5f%5fDBCMFQQ0



_____________________________________________________________________



HP is committed to protecting your privacy. Your information will not be

shared outside HP unless you give your consent. You can choose whether HP

may communicate directly with you. For more information please see the HP

Privacy Statement:

http://alerts.hp.com/r?2.1.3KT.2ZR.1DDl4I.LoI6v2..T.buT4.8tFy.bW89MQ%5f%5fDAVEFQM0



As a valued contact or customer of HP, you are receiving this

eNewsletter with information that we believe will be relevant to you. But

if you do not wish to receive this communication in the future, please

click here to unsubscribe:

http://alerts.hp.com/r?2.1.3KT.2ZR.1DDl4I.LoI6v2..T.buT6.8tFy.bW89MQ%5f%5fDAbYFQO0



© 1994-2012 Hewlett-Packard Company. All rights reserved. All product and

company names referenced herein are trademarks of their respective owners.

THIS DOCUMENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY. INFORMATION

PROVIDED IN THIS DOCUMENT IS PROVIDED AS IS WITHOUT WARRANTY OF ANY KIND,

EITHER EXPRESSED OR IMPLIED. This document may be copied provided all text

is included and copies contain HP's copyright notice and any other notices

provided herein. Any pricing information provided in this newsletter

represents estimated resale pricing. Actual reseller prices may vary.

Comments

Post a Comment

Popular posts from this blog

The first drug for a common, deadly liver disease is here – and more are coming

VIEW IN BROWSER | SUBSCRIBE TUE, MAR 19, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good morning!  Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for the condition.    In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals ' drug " Rezdiffra ," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates.    So, why is this approval so important?    First of all, people suffering from the disease badly need a treatment. Rezdiffra is specifically approved to treat patients with nonalcoholic steatoh
Post a Comment
Read More

J&J, Merck and Bristol Myers Squibb are in the hot seat

VIEW IN BROWSER | SUBSCRIBE TUE, JAN 30, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com .    Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks ahead.    CEOs from those companies are slated to testify at a Senate hearing on high prescription drug prices in the U.S. on Feb. 8 at 10 a.m. ET, Sen. Bernie Sanders announced Friday.   It took subpoena threats from the senator, but J&J CEO Joaquin Duato and Merck CEO Robert Davis have agreed to testify after both executives declined earlier requests to appear at the Senate HELP committee's hearing. They join Bristol Myers Squibb CEO Chris Boerner, who agr
Post a Comment
Read More

How competitive can Roche be in the weight loss drug market?

VIEW IN BROWSER | SUBSCRIBE TUE, SEP 17, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon!  Roche is one of several drugmakers hoping to join the booming weight loss drug market, which Novo Nordisk and Eli Lilly are currently dominating. But can the Swiss company develop drugs that can compete with that duopoly?  The answer isn't clear yet.  We need to see more data from longer and larger clinical trials, which will likely take years for Roche to conduct.  But the company last week presented more early-stage data more early-stage data on its experimental obesity injection and pill, which some analysts said raised concerns about how competitive those products can be if they enter the space. Some analysts said the new results showed that both drugs – which Roche acquired through its nearly $3 billion acquisition of Carmot Therapeutics in December – caused a higher rate of side
Post a Comment
Read More